Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.
Donny Wong

Dr. Donny Wong Ph.D.

Director, Metabolic Disorders, DECISION RESOURCES, INC.

What is a GLG Educator?|GLG Educators have qualified for GLG Member Programs and are therefore eligible to participate in ongoing in-depth consulting projects with GLG clients.

Member of the Healthcare Council

Request a consultation with Donny Wong

Council Member Biography

Donny Wong, Ph.D., is the therapeutic area director for metabolic disorders at Decision Resources, Inc., where he has authored over 30 market research reports covering type 2 diabetes, obesity, dyslipidemia, metabolic syndrome, diabetic complications, and other disorders. Dr. Wong’s research, analysis, and commentaries have appeared in numerous media outlets including the Wall Street Journal, Barron’s, Pharmaceutical Executive, Forbes, In Vivo, PharmaVoice, and BBC America. His previous experience includes 12 years of scientific research conducted at Harvard University, the Massachusetts Institute of Technology, Praecis Pharmaceuticals, and the U.S. Department of Agriculture. Dr. Wong attended MIT and Williams College and earned M.Sc. and Ph.D. degrees from Harvard University. (This is me - Update Profile)


Employment History

2004 - Unspecified
Director, Metabolic Disorders, DECISION RESOURCES, INC.

GLG NewsSM Analyses by Donny Wong(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Improvements to CV risk factors, but magnitude very low

October 27, 2009

Arena: 2nd weight loss trial shows cardiac benefit | www.reuters.com

Arena presented data on lorcaserin at a series of presentations this week at the 2009 meeting of The Obesity Society in Washington DC. Data from both the BLOOM and BLOSSOM Phase III studies were presented, although BLOOM data had been released for some time already.

Unclear how orlistat's mechanism can lead to liver damage. Likely a non-issue.

August 28, 2009

FDA Investigating Reports of Liver Injury in Patients Using Weight Loss Drug Orlistat | www.webmd.com

Orlistat is designed to act peripherally in the GI tract and studies have demonstrated negligible systemic absorption of orlistat. Patients suffering from liver damage are either hypersensitive to orlistat or have taken too much of the drug. It is likely that these cases of liver injury are unrelated to orlistat, since obesity predisposes patients for liver damage. But overall cases of liver damage are small compared to the total number of patients who have taken the drug over the years.

Request a consultation with Donny Wong

GLG Study Groups with Donny Wong(?)

Donny Wong is not a member of any GLG Study Groups.

View All Study Groups

GLG Live Meetings with Donny Wong(?)

Donny Wong has not participated in any GLG Live Meetings.

View all GLG Live Meetings in Healthcare